Albutein Indications/Uses

Albutein is indicated: For treatment of hypovolemic shock.
5%: In conditions in which there is severe hypoalbuminemia. However, unless the pathologic condition responsible for the hypoalbuminemia can be corrected, administration of albumin can afford only symptomatic or supportive relief.
As an adjunct in hemodialysis and in cardiopulmonary bypass procedures.
In those conditions in which the colloid requirement is high and there is less need for fluid, albumin should be administered as a 25% solution.
Pediatric Use: The pediatric use of Albutein 5% has not been clinically evaluated. Therefore, physicians should weigh the risks and benefits of the use of Albutein 5% in the pediatric population.
20% and 25%: As an adjunct in hemodialysis for patients undergoing long-term dialysis or for those patients who are fluid-overloaded and cannot tolerate substantial volumes of salt solution for therapy of shock or hypotension.
In cardiopulmonary bypass procedures; however, the optimum regimen of fluids has not been established.
Condition in which Albumin 20% and 25% MAY BE indicated: Adult respiratory distress syndrome (ARDS).
Major injury or surgery resulting in increased albumin loss or inadequate synthesis.
Acute nephrosis not responding to cyclophosphamide or steroid therapy. Steroid therapy may increase edema which may respond to combined therapy of albumin with a diuretic.
Acute liver failure or ascites where the therapeutic use is regulated by the individual circumstances.
Unless the pathologic condition responsible for hypoalbuminemia can be corrected, administration of albumin can only afford symptomatic relief. There is NO valid reason for the use of albumin as an intravenous nutrient.
Pediatric Use: Albutein 20% and 25% is indicated in conjunction with exchange transfusion in the treatment of neonatal hyperbilirubinemia. The pediatric use of Albutein 20% and 25%, has not been clinically evaluated. Therefore, physicians should weigh the risks and benefits of the use of Albutein 20% and Albutein 25% in the pediatric population.